Why we don't publish 'where to buy' articles for research peptides
Half the peptide content online is vendor marketing with a journalism veneer. Here's our editorial position, why we hold it, and what it costs us.
If you've searched for any research peptide recently — BPC-157, CJC-1295, GHK-Cu, TB-500 — you've seen the pattern. Google the name, find a site ranking in the top 5 with a "[peptide] guide" or "where to buy [peptide] in 2026" title. Click in. A dozen paragraphs of mechanism explainer. Then a ranked list of vendors with affiliate links. Editorial tone, commercial architecture. The reader can't easily tell which one is which.
We don't publish that content. It's worth explaining why, because our decision has costs.
The FDA's actual position on 'research use only'
Vendors selling unapproved peptides typically label them 'for research use only, not for human consumption.' Many people read this as a legal safe harbor — buy the peptide for research, do what you want. The FDA's actual position is different and, over the past few years, has become unambiguous: the RUO disclaimer is void when the vendor or the sites linking to them also publish dosing information, sell bacteriostatic water alongside the product, show human-use imagery, or make therapeutic claims.
A site that publishes "best peptides for joint recovery" followed by "here's where to buy BPC-157" with dosing instructions creates exactly the enforcement nexus the FDA used in its December 2024 warning letters to Summit Research Peptides, Prime Peptides, Xcel Peptides, and SwissChems. The warning letters were directed at the vendors, but the editorial pattern that contributes to the enforcement case is shared.
What this costs us
Real money. High-intent commercial queries — "buy BPC-157," "best tirzepatide vendor," "where to purchase semaglutide" — are among the most valuable SERPs in the niche. Sites that rank for them can command $50–$300 per conversion on affiliate links. We're choosing not to compete for those queries. Our SEO targets are deliberately lower-intent: evidence explainers, regulatory coverage, comparison pages that settle what the data shows. Those rank too, and they don't create the legal problem.
What we'll do instead
Two surfaces concentrate our affiliate revenue, and both are editorial, not transactional.
**Telehealth GLP-1 providers for FDA-approved drugs.** Hims, Ro, Henry Meds, MEDVi, and others prescribe branded Wegovy and Zepbound — FDA-approved products with established safety profiles. These are legitimate commercial relationships for legitimate products, and the editorial coverage sits alongside the affiliate link without either contaminating the other.
**Vendor transparency coverage when the vendor has earned it.** We'll eventually publish vendor reviews, but framed around transparency, compliance, and Certificate-of-Analysis practice — not as buying guides. If a vendor is reviewed here, it's because they're publicly willing to be evaluated on evidence-based criteria.
Our rule
Every vendor or provider mentioned on this site must have an active affiliate relationship with us. If we can't monetize them, we won't feature them. The inverse is also true: if we can't stand behind them editorially, we won't partner with them, regardless of commission rate.
This is an editorial position with both ethical and legal dimensions. We think it's the right one. If it costs us readers who want a buying guide, we're okay with that. There are plenty of places online willing to write the other kind of article.
Sources